Clinical Trials on SGLT2 INHIBITORS in Hong Kong
Total 6 results
-
The University of Hong KongResearch Grant CouncilRecruitingCirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 InhibitorsHong Kong
-
Prof. Stephen LeePfizer; Queen Mary Hospital, Hong KongCompletedCoronary Disease | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Ultrasonography, InterventionalChina
-
Chinese University of Hong KongNanfang Hospital, Southern Medical UniversityRecruitingProton Pump Inhibitors | Upper GI BleedingChina
-
The University of Hong KongRecruitingRecurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH MutationHong Kong
-
Samsung Medical CenterCompletedAdherence, Medication | Percutaneous Coronary Intervention | Compliance, Medication | Platelet Aggregation Inhibitors | Hydroxymethylglutaryl-coa Reductase Inhibitors | Persistence, MedicationKorea, Republic of
-
Eli Lilly and CompanyActive, not recruitingUrogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditionsChina, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece